Celine Loncle
Overview
Explore the profile of Celine Loncle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu J, Chen C, Wei T, Gayet O, Loncle C, Borge L, et al.
Exploration (Beijing)
. 2023 Jun;
1(1):21-34.
PMID: 37366462
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with no efficacious treatment. The application of nanomedicine is expected to bring new hope to PDAC treatment. In this study, we report...
2.
Cano C, Jose Sandi M, Hamidi T, Calvo E, Turrini O, Bartholin L, et al.
EMBO Mol Med
. 2021 May;
13(5):e14243.
PMID: 33960146
No abstract available.
3.
Benyamine A, Loncle C, Foucher E, Blazquez J, Castanier C, Chretien A, et al.
Oncoimmunology
. 2018 Jan;
7(1):e1372080.
PMID: 29296524
Vγ9Vδ2 T cells are anti-tumor immune effectors of growing interest in cancer including Pancreatic Ductal Adenocarcinoma (PDAC), an especially aggressive cancer characterized by a hypoxic and nutrient-starved immunosuppressive microenvironment. Since...
4.
Nicolle R, Blum Y, Marisa L, Loncle C, Gayet O, Moutardier V, et al.
Cell Rep
. 2017 Nov;
21(9):2458-2470.
PMID: 29186684
Preclinical models based on patient-derived xenografts have remarkable specificity in distinguishing transformed human tumor cells from non-transformed murine stromal cells computationally. We obtained 29 pancreatic ductal adenocarcinoma (PDAC) xenografts from...
5.
Bian B, Bigonnet M, Gayet O, Loncle C, Maignan A, Gilabert M, et al.
EMBO Mol Med
. 2017 Mar;
9(4):482-497.
PMID: 28275007
controls more than 15% of genes responsible for proliferation, differentiation, and cellular metabolism in pancreatic as well as other cancers making this transcription factor a prime target for treating patients....
6.
Leca J, Martinez S, Lac S, Nigri J, Secq V, Rubis M, et al.
J Clin Invest
. 2016 Oct;
126(11):4140-4156.
PMID: 27701147
The intratumoral microenvironment, or stroma, is of major importance in the pathobiology of pancreatic ductal adenocarcinoma (PDA), and specific conditions in the stroma may promote increased cancer aggressiveness. We hypothesized...
7.
Barraud M, Garnier J, Loncle C, Gayet O, Lequeue C, Vasseur S, et al.
Oncotarget
. 2016 Jul;
7(33):53783-53796.
PMID: 27462772
Treating pancreatic cancer is extremely challenging due to multiple factors, including chemoresistance and poor disease prognosis. Chemoresistance can be explained by: the presence of a dense stromal barrier leading to...
8.
Loncle C, Bonjoch L, Folch-Puy E, Lopez-Millan M, Lac S, Molejon M, et al.
Cancer Res
. 2016 Mar;
76(7):2051.
PMID: 26992425
No abstract available.
9.
Grasso D, Bintz J, Lomberk G, Molejon M, Loncle C, Garcia M, et al.
Sci Rep
. 2015 Dec;
5:17549.
PMID: 26617245
Nupr1 is a chromatin protein, which cooperates with Kras(G12D) to induce PanIN formation and pancreatic cancer development in mice, though the molecular mechanisms underlying this effect remain to be fully...
10.
Loncle C, Bonjoch L, Folch-Puy E, Lopez-Millan M, Lac S, Molejon M, et al.
Cancer Res
. 2015 Sep;
75(22):4852-62.
PMID: 26404002
Pancreatic ductal adenocarcinoma (PDAC) offers an optimal model for discovering "druggable" molecular pathways that participate in inflammation-associated cancer development. Chronic pancreatitis, a common prolonged inflammatory disease, behaves as a well-known...